Home About Us Services Our Network Therapeutic Areas Alliance and Partner FAQ Training
Case Study
Phase III Vaccine Non – Inferiority study – WHO Submission
Major Vaccine Manufactures

 

  • Number of Studies Conducted: 3
  • Client: Indian Sponsor
  • Requirements: Client approached D2L to provide about (5+2+5) pediatric sites for 3 studies
  • Site feasibility was based on
    • Experienced Sites
    • High Birth Rate
    • Patient Recruitment - Avg. recruitment of 70 subjects/month
    • Turn around time for getting EC Approvals


Highlights of D2L Support

  • Identified and provided the required sites in each of studies with less than a week of turn around time
  • Conducted Pre Site Selection Visit (PSSV) to Identified Sites
  • Developed Infrastructure at each site
  • EC submissions completed within two weeks
  • Assisted in getting faster approvals from the ECs
  • Provided Protocol Specific Training to Investigators & CRC’s at each sites
  • Achieved the target subject recruitment within 25 days
  • Internal pre-monitoring visits from D2L to each sites ensured high quality & subject retention
  • Drop- Out Rates – less than 5 %
  • Three sites successfully audited by the Sponsor
<< Back to Casestudy List
Casestudy | Career | Clientele | News | Contact Us
NEWS & MEDIA
InterVein Labs, D2L Pharma join hands
read more..

D2L-SMO at International Level Career Development Seminar for Biological Science Students held at Convention Centre, Kattankulathur, SRM University, Chennai
read more..

D2L-SMO to be present in the 16th International Seminar on "Global Clinical Trial Management and Logistics" organized by World Courier
read more..

D2L-SMO & Intervein Labs to be present at the DIA 44th Annual Meeting held on 22nd -26th June 2008 in Boston Convention & Exhibition Center, Boston
read more..

All rights reserved 2008 ©D2L-SMO   |  Terms and Conditions  |  Privacy Policy  |  Disclaimer      
Phone : 91 - 80 - 3245 0009 / 41743601
Fax : +91-80-41534831
Email : info@d2lpharma.com